COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a boost to the Danish drugmaker’s new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.

The Danish company said it lowered its full-year profit forecast, while also lowering the top end of its full-year sales forecast range.

The rise in sales in local currency terms, which has slowed sharply in the last year as competition has risen from rival Eli Lilly and copycat treatments, compared with 11.4% growth expected by analysts in a company-compiled consensus.

Novo shot to become Europe’s most valuable firm on the back of rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow, spark

See Full Page